Company news

Invivyd, Inc. news in 2023

Invivyd, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

December 17, 2023

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 8, 2023

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

November 1, 2023

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

September 10, 2023

Invivyd Appoints William Duke as Chief Financial Officer

September 4, 2023

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

August 9, 2023

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

August 2, 2023

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

July 26, 2023

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

July 16, 2023

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

June 25, 2023

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

June 21, 2023

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

April 24, 2023

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

April 11, 2023

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

March 29, 2023

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

March 22, 2023

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

March 5, 2023

Invivyd Announces Changes to Executive Team

February 2, 2023

Calls in 2023

Decks in 2023